Health Care & Life Sciences » Biotechnology | Fate Therapeutics Inc.

Fate Therapeutics Inc.

Fate Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.23
Market Cap
$1.38 B
Shares Outstanding
65.19 M
Public Float
56.64 M

Profile

Address
3535 General Atomics Court
San Diego California 92121
United States
Employees -
Website http://www.fatetherapeutics.com
Updated 07/08/2019
Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy.

Financials

View All

J. Scott Wolchko
President, Chief Executive Officer & Director
Michael Stewart Lee
Director